Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 53 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Wechelpharma from Lille, company number BE0885230908, closed financial year 2025 with a result of € 653,281 after tax. For that financial year Wechelpharma recorded a gross margin of € 164,612 and equity of € 1.9 million. Compared with financial year 2024, the result moved from € 155,814 to € 653,281. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on March 23, 2026.
€ 1.9 million
▲ 55% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 653,281
▲ € 497,467 vs 2024
Profit after tax over the fiscal year.
€ 8,190
▼ 26% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 1.8 million.
People and assets in 2025
€ 3,469
▼ 71% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 53
▼ 98% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 56,322
▲ € 47,163 vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 189,031 | € 195,277 | € 165,568 | € 164,612 | ▼ 1% |
| Profit after taxes | € 186,946 | € 163,590 | € 155,814 | € 653,281 | ▲ € 497,467 |
| Equity | € 1,172,381 | € 1,201,192 | € 1,197,329 | € 1,850,611 | ▲ 55% |
| Total debts | € 1,092,578 | € 1,004,654 | € 997,063 | € 630,450 | ▼ 37% |
| Cash | € 43,861 | € 17,870 | € 11,025 | € 8,190 | ▼ 26% |
| Retained profit | € 1,153,831 | € 1,182,642 | € 1,178,779 | € 1,832,061 | ▲ 55% |
| Dividend | € 0 | € 134,779 | € 159,677 | € 0 | ▼ 100% |
| Bank debt | € 12,636 | € 2,543 | € 0 | € 0 | |
| Balance sheet total | € 2,264,959 | € 2,205,845 | € 2,194,392 | € 2,481,060 | ▲ 13% |
Key figures of Wechelpharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Wechelpharma?
What happened at Wechelpharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 653,281 (▲ € 497,467 vs 2024). Source: NBB ↗
- New establishment in Lille. KBO
- Jeroen Peeters became a director. NBB
- Brigitte Dekeyser became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 186,946 profit in 2022 to € 653,281 profit in 2025.
Paid € 214,909 in corporate taxes since 2022.
Best year ever: 2025, with € 653,281 profit.
Paid out € 294,456 in dividends to the owners in total.
Management
Behind Wechelpharma are Jeroen Peeters and Brigitte Dekeyser. It owns 99.7% of Apotheek Peeters-Dekeyser itself.
Directors
According to the 2025 annual accounts
since 2006
Brigitte Dekeyser
Bestuurder
since 2006
Establishments
Establishment units
Physical locations of this company
Gebroeders De Winterstraat 32
2275 Lille
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0885.230.908
- VAT number
- BE 0885.230.908
- Registered office
- Gebroeders De Winterstraat 32, 2275 Lille
- Names & denominations
- Wechelpharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 November 2006
- Peppol
- Active · Active since 24 Nov 2023
- Activities · NACE
Activiteiten van holdings
Managementactiviteiten van holdings
Holdings